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Immune reactions are among the most serious complications observed after hematopoietic stem cell transplantation (HSCT) in
children. Microarray technique allows for simultaneous assessment of expression of nearly all human genes. The objective of the
studywas to compare thewhole genome expression in children before and afterHSCT. A total of 33 children referred forHSCTwere
enrolled in the study. In 70% of the patients HSCT was performed for the treatment of neoplasms. Blood samples were obtained
before HSCT and six months after the procedure. Subsequently, the whole genome expression was assessed in leukocytes using
GeneChip Human Gene 1.0 ST microarray. The analysis of genomic profiles before and after HSCT revealed altered expression of
124 genes. Pathway enrichment analysis revealed upregulation of five pathways after HSCT: allograft rejection, graft-versus-host
disease, type I diabetes mellitus, autoimmune thyroid disease, and viral myocarditis. The activation of those pathways seems to
be related to immune reactions commonly observed after HSCT. Our results contribute to better understanding of the genomic
background of the immunologic complications of HSCT.
1. Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT)
has progressed from a risky experimental therapy to a safe
and life-saving treatment modality in a relatively short span
of five decades [1]. However, transplant recipients still require
prolonged treatment with multiple, nonspecific, and toxic
immunosuppressive drugs and are at a constant risk of
immune reactions which may lead to graft-versus-host dis-
ease (GvHD) or graft rejection (GR). Immune reactions result
from the activation of donor lymphocytes with subsequent
recognition of the host’s antigens, emergence of effector T
cells, production of alloantibodies, and infiltration of tissues
by alloreactive cells [2].
The aim of the study was to analyze the spectrum of
alterations of genome expression resulting from HSCT.
2. Materials and Methods
This was a prospective study conducted from May 2009
to September 2012. The study group consisted of children
and teenagers referred for HSCT, which was performed
according to disease-specific treatment protocols. The study
was approved by the Ethics Committee of the Jagiellonian
University (KBET/96/B/2008). Written informed consent
was obtained from all parents and from all patients ≥ 16 years
of age.
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Table 1: The indications for HSCT (pre-HSCT group).
Condition 𝑛 (%)
Acute lymphoblastic leukemia (ALL) 15 (36)
Acute myeloblastic leukemia (AML) 5 (15)
Acute bilineage leukemia (ABL) 1 (3)
Juvenile myelomonocytic and acute myeloblastic
leukemia (JMML/AML) 1 (3)
Myelodysplastic syndrome (MDS) 1 (3)
Neoplasms (total) 23 (70)
Severe aplastic anemia (SAA) 4 (12)
Chronic granulomatous disease (CGD) 3 (9)
Autoimmune lymphoproliferative syndrome (ALPS) 1 (3)
Hyper-IgM syndrome (HIgM) 1 (3)
Inherited neutropenia (IN) 1 (3)
Nonneoplastic conditions (total) 10 (30)
2.1. Microarray Analysis. Blood samples (1.5mL) were col-
lected from each patient before conditioning and approx-
imately six months after HSCT (median 6.3 months).
We assessed the whole genome expression in peripheral
blood leukocytes using GeneChip Human Gene 1.0 ST
Array (Affymetrix, Santa Clara, USA). Total RNA extraction
was performed using RiboPure Blood Kit (Ambion, Life
Technologies, Carlsbad, USA). Whole transcript microarray
experiment was performed according to the manufacturer’s
protocol (GeneChipWhole Transcript Sense Target Labeling
Assay Manual, Version 4).
2.2. Statistical Analysis. Study sample size ensures adequate
power to detect a 1.5-fold change. The microarray data
were preprocessed using the R/Bioconductor package [3–5].
Robust Multiarray Average (RMA) was used for normaliza-
tion [6]. Quality control was performed by investigating Prin-
cipal Component Analysis (PCA), Relative Log Expression
(RLE), and Normalized Unscaled Standard Error (NUSE)
plots.
Moderated 𝑡-tests [7]were performed to detect the probes
that were differentially expressed between groups, using
the limma package [8] in the R statistical software. It was
assumed that the log
2
transformed gene expression levels
are normally distributed and the between-group variation
is of comparable magnitude. Multiple testing correction
(Benjamini-Hochberg procedure) was applied to control the
false discovery rate (FDR) [9]. Significantly different expres-
sion in the probe sets was defined as multiple comparison-
corrected two-sided 𝑝 value < 0.05.
DAVID annotation tools were used to compare gene set
enrichment between the groups [10, 11]. The KEGG (Kyoto
Encyclopedia of Genes and Genomes; http://www.genome
.jp/kegg/) and Biocarta (http://www.biocarta.com/) path-
ways were selected for analysis. A set of top 250 differentially
expressed genes (TOP 250 database) was exported for path-
way enrichment analysis.
Table 2: Characteristics of studied groups.
Pre-HSCT group
𝑁 33
Sex Boys 25, girls 8
Age (years) 1.5–19 (median 10.5)
Chemotherapy before HSCT (%) 23 (71%)
First line 13
Second line 9
≥third line 1
Local radiotherapy 7
Cranial (dose) 5 (12Gy-4, 18Gy-1)
Testes (dose) 2 (12Gy/24Gy, 18Gy/18Gy)
Time since diagnosis and patient
selection (years) Median, 1.4; range 0.08–12.9
Post-HSCT group
𝑁 20
Sex Boys 14, girls 7
Age (years) 2.8–19.5 (median 9.6)
Conditioning regimen based on
busulfan (𝑛) 9 (45%)
Total body irradiation, 12Gy/6
fractions (𝑛) 6 (30%)
GvHD prophylaxis (𝑛)
Ciclosporin 2 (10%)
Methotrexate + ciclosporin 18 (90%)
GvHD (𝑛) 14 (70%)
Median time from HSCT to the
second assessment (range) 6.4 (6–13) months
Systemic glucocorticoids (%) 16 (80%)
Median and range of cumulative
dose of glucocorticoids
(equivalent of prednisone)
1463 (29–9758)mg/m2
Median duration of systemic
glucocorticoids therapy 105 (3–240) days
Median time since
discontinuation of
glucocorticoids (range)
3.5 (0.4–14.3) months
Median time from
discontinuation of
immunosuppressive treatment to
the second assessment (range)
(16 patients)
1.8 (0–9) months
3. Results
3.1. Characteristic of the Study Group. The group of patients
assessed before HSCT (pre-HSCT group) included 33
patients aged 1.5–19 (median 10.5) years, referred to the
StemCell Transplantation Centre of the University Children’s
Hospital in Krakow. The indications for HSCT are listed in
Table 1. Characteristics of children referred for HSCT are
presented in Table 2.
The group of patients assessed after HSCT (post-HSCT
group) included 20 children from the pre-HSCT group,
aged 2.8–19.5 (median 9.6) years. In six patients in the pre-
HSCT group the results of the microarray analysis were
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Table 3: Summary of the number of differentially expressed genes between studied groups.
Study groups Genes with significant differences revealed afterBenjamini-Hochberg correction
Number of genes with expression fold change ≥ 1.5
+1.5 −1.5
Post-HSCT/pre-HSCT
13
Fold change
+1.5–0
−1.5–1
44 80
not reliable for technical reasons (poor quality of RNA
sample) and another three patients were lost to follow-up.
Four children died due to complications of treatment or
disease progression. All patients in the post-HSCT group
were treated with ablative conditioning regiments. The key
clinical characteristics of the post-HSCT group are presented
in Table 2.
3.2. Whole Genome Expression. All the primary microarray
data were submitted to GEO public repository and are
accessible using GEO Series accession number GSE69421
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE-
32472).
A summary of the differentially expressed genes is pre-
sented in Table 3.
A comparison of the pre-HSCT group and post-HSCT
group revealed 124 genes with difference in expression and
fold change ≥ 1.5. For 36% of these genes the expression was
higher in the post-HSCT group (Table 3).
3.3. Pathway Enrichment Analysis. Based on the results pre-
sented in Table 4, pathway enrichment analysis was per-
formed.
The genes showing overexpression in the post-HSCT
group compared with the pre-HSCT group formed pathways
responsible for donor/recipient alloaggression, including
“allograft rejection” and “graft-versus-host disease,” which
represent themost common complications ofHSCT aswell as
pathways representing immunologic reaction against specific
organs (“type I diabetes mellitus,” “autoimmune thyroid
disease,” and “viral myocarditis”), which are among the late
complications of HSCT. At the same time parallel activation
of genes forming “antigen processing and presentation” path-
way was observed.
The genes showing underexpression in the post-HSCT
group compared with the pre-HSCT group represent path-
ways regulating erythropoiesis and metabolism of proteins.
As analysis was performed after intensive proliferation due
to reconstitution of hematopoiesis, inhibition of these genes
might have occurred. The pathway “Th1/Th2 Differentiation”
could be inhibited as a result of prolonged immunosuppres-
sive treatment used for GvHD prevention in most patients
treated with HSCT.
4. Discussion
Acute graft-versus-host disease (aGvHD) is the leading cause
of morbidity and mortality after HSCT that affects the skin,
liver, and gastrointestinal tract and contributes to transplant-
related morbidity and mortality [2]. Approximately 50% of
patients treated with HSCT subsequently develop aGvHD
and require systemic treatment [12]. Chronic graft-versus-
host disease (cGvHD) occurs in 40% of patients treated
with HSCT from an HLA-identical sibling and in more
than 50% of patients treated with HSCT from an HLA-
nonidentical related donor and in 70%of patients treatedwith
HSCT from an HLA-matched unrelated donor. The onset of
symptoms is within a median of 133 days after an unrelated
donor HSCT [13]. cGvHD is an immunoregulatory disorder
occurring after allogeneic HSCT and has clinical features
of both autoimmune disorder and immunodeficiency. The
features of cGvHD resemble other autoimmune diseases such
as Sjögren syndrome, scleroderma, primary biliary cirrhosis,
and immune cytopenia [14]. Graft rejection (GR) occurs
in 12% of children undergoing allogeneic HSCT within a
median of 63 days after the transplantation [15]. Our study
revealed that the genes showing overexpression in the post-
HSCT group compared with the pre-HSCT group formed
the pathways responsible for “allograft rejection” and “graft-
versus-host disease” thus giving genetic background for the
observed immune reactions. Even though no case of GR
was observed in the study group, the activation of the
genes responsible for GR is obvious, and our results suggest
the effectiveness of the preventive treatment used in these
patients.
The microarray analysis indicated presence of three
other pathways: “type I diabetes mellitus,” “autoimmune
thyroid disease,” and “viral myocarditis.” The incidence of
compensated hypothyroidism in patients after HSCT ranges
from 25 to 30% with a median latency of 2 years; overt
hypothyroidism is diagnosed in up to 9% of patients with a
latency of 2.7 years. Younger age is associated with higher risk
of hypothyroidism [16, 17]. Patients treated with HSCT also
have 2.3- to 4.0-fold higher risk of death due to cardiac causes
compared with the general population [18, 19]. The cumu-
lative incidence of cardiovascular diseases approaches 23%
at 25 years after HSCT and is highest among the allogeneic
HSCT recipients.The incidence appears to increase with time
[20, 21]. Moreover, the patients treated withHSCT are known
to have an increased risk of diabetes mellitus [22]. The risk
of diabetes adjusted for age, sex, race, and BMI is 3.7 times
higher in patients after allogeneic HSCT compared with the
general population [23].
Activated T cells play additional important role in
controlling a variety of critical steps after HSCT, such as
facilitating engraftment of hematopoietic stem cells, immune
reconstitution, and elimination of residual disease, but they
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are also responsible for immune reactions against the host’s
tissues [24, 25]. Our data support the hypothesis on the role
of activation of gene machinery resulting in aggression of
donor immune system against specific host organs leading
to deterioration of their function. Regulatory T cells have
been shown to mitigate immune reactions after HSCT by
suppressing the early expansion of donor T cells [26].
So far, there is no validated diagnostic or predictive
blood biomarker for GvHD which could improve diagnosis
and prognosis and help to guide therapeutic interventions
[26, 27]. Currently, the diagnosis of GvHD is based on
clinical manifestations in one or more of the main target
organs and on biopsy results. Moreover, once GvHD occurs,
the most important predictor of long-term survival is the
primary response to therapy. In patients who are resistant to
initial therapy, the risk of morbidity and mortality increases
significantly [28, 29]. Thus, there is a need to identify new
biomarkers to predict not only GvHD development but also
the survival and treatment outcomes of GvHD. Future studies
might answer the question whether specific gene expression
patterns can be used as biomarkers of immune complications
after HSCT.
In conclusion, the results of ourwhole genome expression
study revealed altered expression of the genes responsible
for immune reactions against recipient/donor cells, proving
genetic background for one of the most common complica-
tions (GvHD, GR), observed after HSCT.
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